Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 24083612)


HIV-1 inhibiting capacity of novel forms of presentation of GB virus C peptide domains is enhanced by coordination to gold compounds.

Gómara MJ, Galatola R, Gutiérrez A, Gimeno MC, Gatell JM, Sánchez-Merino V, Yuste E, Haro I.

Curr Med Chem. 2014;21(2):238-50. Review.


Surface behavior of peptides from E1 GBV-C protein: Interaction with anionic model membranes and importance in HIV-1 FP inhibition.

Galatola R, Cruz A, Gómara MJ, Prat J, Alsina MA, Haro I, Pujol M.

Biochim Biophys Acta. 2015 Feb;1848(2):392-407. doi: 10.1016/j.bbamem.2014.10.033. Epub 2014 Oct 30.


A cyclic GB virus C derived peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1.

Galatola R, Vasconcelos A, Pérez Y, Cruz A, Pujol M, Alsina MA, Gómara MJ, Haro I.

Eur J Med Chem. 2014 Oct 30;86:589-604. doi: 10.1016/j.ejmech.2014.09.020. Epub 2014 Sep 8.


Cell-penetrating, dimeric α-helical peptides: nanomolar inhibitors of HIV-1 transcription.

Jang S, Hyun S, Kim S, Lee S, Lee IS, Baba M, Lee Y, Yu J.

Angew Chem Int Ed Engl. 2014 Sep 15;53(38):10086-9. doi: 10.1002/anie.201404684. Epub 2014 Jul 23.


Design of antiviral stapled peptides containing a biphenyl cross-linker.

Muppidi A, Zhang H, Curreli F, Li N, Debnath AK, Lin Q.

Bioorg Med Chem Lett. 2014 Apr 1;24(7):1748-51. doi: 10.1016/j.bmcl.2014.02.038. Epub 2014 Feb 22.


Anti-HIV activities of novel synthetic peptide conjugated chitosan oligomers.

Karagozlu MZ, Karadeniz F, Kim SK.

Int J Biol Macromol. 2014 May;66:260-6. doi: 10.1016/j.ijbiomac.2014.02.020. Epub 2014 Feb 18.


Modification of FP-HIV activity by peptide sequences of GB virus C: a biophysical approach.

Domènech O, Ortiz A, Pujol M, Haro I, Muñoz M, Alsina MA, Prat J, Busquets MA, Girona V.

Biochim Biophys Acta. 2014 May;1838(5):1274-80. doi: 10.1016/j.bbamem.2014.02.001. Epub 2014 Feb 11.


Phylogenetic Diversity of GB Virus C at the Antigenic Site of E2 Protein.

Wu H, Tien P, Gong X.

Virus Res. 2013 Oct 25. pii: S0168-1702(13)00358-4. doi: 10.1016/j.virusres.2013.10.011. [Epub ahead of print]


Impact of GB virus C viraemia on clinical outcome in HIV-1-infected patients: a 20-year follow-up study.

Ernst D, Greer M, Akmatova R, Pischke S, Wedemeyer H, Heiken H, Tillmann HL, Schmidt RE, Stoll M.

HIV Med. 2014 Apr;15(4):245-50. doi: 10.1111/hiv.12094. Epub 2013 Oct 7.


GB virus C particles inhibit T cell activation via envelope E2 protein-mediated inhibition of TCR signaling.

Bhattarai N, McLinden JH, Xiang J, Landay AL, Chivero ET, Stapleton JT.

J Immunol. 2013 Jun 15;190(12):6351-9. doi: 10.4049/jimmunol.1300589. Epub 2013 May 17.


GB virus C infection in Indonesian HIV-positive patients.

Anggorowati N, Yano Y, Subronto YW, Utsumi T, Heriyanto DS, Mulya DP, Rinonce HT, Widasari DI, Lusida MI, Soetjipto, Hayashi Y.

Microbiol Immunol. 2013 Apr;57(4):298-308. doi: 10.1111/1348-0421.12033.


HIV-1 fusion is blocked through binding of GB Virus C E2-derived peptides to the HIV-1 gp41 disulfide loop [corrected].

Eissmann K, Mueller S, Sticht H, Jung S, Zou P, Jiang S, Gross A, Eichler J, Fleckenstein B, Reil H.

PLoS One. 2013;8(1):e54452. doi: 10.1371/journal.pone.0054452. Epub 2013 Jan 22. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/b46459e1-73ff-4b75-8f24-264cbcf4a5a9.


Chimpanzee GB virus C and GB virus A E2 envelope glycoproteins contain a peptide motif that inhibits human immunodeficiency virus type 1 replication in human CD4⁺ T-cells.

McLinden JH, Stapleton JT, Klinzman D, Murthy KK, Chang Q, Kaufman TM, Bhattarai N, Xiang J.

J Gen Virol. 2013 Apr;94(Pt 4):774-82. doi: 10.1099/vir.0.047126-0. Epub 2013 Jan 3.


Enhancement of anti-HIV-1 activity by hot spot evolution of RANTES-derived peptides.

Secchi M, Longhi R, Vassena L, Sironi F, Grzesiek S, Lusso P, Vangelista L.

Chem Biol. 2012 Dec 21;19(12):1579-88. doi: 10.1016/j.chembiol.2012.10.007.


Design and application of GB virus C (GBV-C) peptide microarrays for diagnosis of GBV-C/HIV-1 co-infection.

Fernández L, Bleda MJ, Gómara MJ, Haro I.

Anal Bioanal Chem. 2013 May;405(12):3973-82. doi: 10.1007/s00216-012-6585-3. Epub 2012 Dec 13.


Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.

Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.

J Virol. 2013 Feb;87(3):1649-57. doi: 10.1128/JVI.02201-12. Epub 2012 Nov 21.


Intra-host diversity and emergence of unique GBV-C viral lineages in HIV infected subjects in central China.

Wu H, Padhi A, Xu J, Gong X, Tien P.

PLoS One. 2012;7(11):e48417. doi: 10.1371/journal.pone.0048417. Epub 2012 Nov 12.


Role of GB virus C in HIV-1-infected and hepatitis C virus-infected hemophiliac children and adolescents.

Tenckhoff S, Kaiser T, Bredeek F, Donfield S, Menius E, Lail A, Mössner J, Daar ES, Tillmann HL.

J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):243-8.


GB virus C infection is associated with a reduced rate of reactivation of latent HIV and protection against activation-induced T-cell death.

Rydze RT, Bhattarai N, Stapleton JT.

Antivir Ther. 2012;17(7):1271-9. doi: 10.3851/IMP2309. Epub 2012 Sep 5.


Physicochemical characterization of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide: interaction with model membranes.

Sánchez-Martín MJ, Cruz A, Busquets MA, Haro I, Alsina MA, Pujol M.

Int J Pharm. 2012 Oct 15;436(1-2):593-601. doi: 10.1016/j.ijpharm.2012.07.051. Epub 2012 Jul 31.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk